Peptides are short chains of amino acids held together by peptide bonds. Unlike many small-molecule compounds, they carry chemically reactive groups along their sequence. Heat, moisture, oxygen, and light can all drive reactions that break or alter them. So most research peptides require refrigeration during storage and a cold chain during shipping, and that requirement does not disappear once a vial is reconstituted.
Why peptides degrade
The pharmaceutical literature describes four main degradation pathways. Hydrolysis is water cleaving susceptible bonds, particularly around aspartic acid residues. Oxidation affects methionine, cysteine, and tryptophan residues. Deamidation converts asparagine and glutamine residues to acidic forms, often via an aspartimide intermediate. Aggregation is peptide chains clumping into larger, biologically inactive structures. Temperature speeds up all of them. Research summarized via PubMed and technical notes from manufacturers such as Bachem describe the rate of chemical degradation roughly doubling for every 10 °C rise in temperature. That rule of thumb comes from the Arrhenius equation and is widely cited in peptide and protein formulation literature, though the exact factor varies by reaction and sequence.
Lyophilized (freeze-dried) powder is more stable than liquid because removing water limits hydrolysis. Even so, lyophilized peptides are commonly stored at −20 °C or below for long-term preservation, and at 2–8 °C for shorter-term use. Bachem's own care-and-handling guidance recommends storage below −15 °C for maximum stability. It also notes peptides are hygroscopic and advises that vials be brought to room temperature in a desiccator before opening. Reconstituted solutions — powder dissolved in bacteriostatic water or another solvent — are far more vulnerable. Water is now present, hydrolysis can proceed, and microbial growth becomes a risk. Reconstituted vials are therefore kept refrigerated and used within a timeframe described in the product's technical documentation, which varies by compound.
Some peptides are more sensitive than others because of their structure. Sequences containing cysteine, methionine, or tryptophan are prone to oxidation. Asparagine or glutamine make a peptide prone to deamidation. Multiple hydrophobic residues make it prone to aggregation. The formulation literature generally describes all of these as higher-risk. Peptides that include disulfide bridges, the structural bonds between two cysteine residues, can lose biological activity if those bridges are disrupted by improper storage.
The cold chain in shipping
A cold chain is an unbroken temperature-controlled sequence from the point of manufacture through transit to the end recipient. For peptides, that usually means insulated packaging with gel packs or dry ice, routing chosen to minimize time in transit, and labeling that communicates temperature requirements to handlers. Regulatory guidance from bodies such as the FDA and EMA for pharmaceutical-grade products specifies Good Distribution Practice (GDP) requirements that include continuous temperature monitoring and documented handling of excursions; for cold-chain products the EU GDP framework generally centers on maintaining a 2–8 °C range. Research-use peptide vendors operate under varying standards, but the underlying chemistry is the same regardless of regulatory category.
A temperature excursion is a period during which a shipment exceeds its specified temperature range. It does not automatically destroy a peptide, but it does increase cumulative degradation. The longer and warmer the excursion, the greater the potential loss of purity and potency. Independent testing laboratories such as Janoshik publish certificates of analysis with HPLC purity figures, and aggregators such as Finnrick collate and publish such results across many vendors; lower-than-expected purity can reflect poor synthesis, poor storage, or both. End users cannot observe what happened during transit, so an intact cold chain is the evidence-based safeguard against receiving a degraded product.
What this means for storage conditions
| State | Typical guidance (from manufacturer documentation) | Key risk if ignored |
|---|---|---|
| Lyophilized powder, long-term | −20 °C or below | Slow hydrolysis, oxidation over months/years |
| Lyophilized powder, short-term | 2–8 °C (refrigerator) | Moisture ingress if container seal is poor |
| Reconstituted solution | 2–8 °C; use within days to weeks | Rapid hydrolysis, microbial growth |
| Any form, in transit | Cold chain with monitoring | Temperature excursions accelerating all pathways |
Suppliers commonly advise keeping vials sealed until use, minimizing repeated temperature cycling (freeze-thaw cycles can stress peptide structure), and storing away from light. These recommendations appear consistently across technical datasheets from manufacturers such as Bachem and PolyPeptide Group, and are echoed in community-aggregated resources.
Peptides sold for research use are not approved for human consumption, and the storage guidance referenced here is drawn from technical and manufacturing literature rather than clinical protocols.
Sources
- Bachem — Care and Handling of Peptides
- PolyPeptide Group — Technical Resources
- Sigma-Aldrich — Peptide Stability and Potential Degradation Pathways
- PubMed — peptide stability and degradation
- FDA — Good Distribution Practice / cold chain
- EMA — Guidelines on Good Distribution Practice
- Finnrick — independent peptide testing results and ratings
- Janoshik — independent peptide testing laboratory